NCT06456463 2026-03-09
TRILLIUM
Stemline Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06498973 2026-03-05
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT07148180 2026-02-05
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05442216 2026-01-23
TAGALONG
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT03113643 2025-11-04
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05233618 2025-05-28
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
University of Virginia
Phase 1 Recruiting
NCT06561152 2025-03-17
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University
Phase 1/2 Recruiting
NCT04342962 2025-01-30
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT02270463 2024-10-17
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Stemline Therapeutics, Inc.
Phase 1/2 Terminated
NCT02113982 2024-08-01
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT05720988 2024-03-08
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn